Hitz, Felicitas <br/><br/>
Rituximab, bendamustine and lenalidomide in patients with aggressive B-cell lymphoma not eligible for anthracycline-based therapy or intensive salvage chemotherapy - SAKK 38/08.  [electronic resource] 

 -  British journal of haematology  07 2016 
 - 255-63 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study 
<br/><br/><label>ISSN: </label>1365-2141 
<br/><br/><label>Standard No.: </label>10.1111/bjh.14049  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Anthracyclines--administration & dosage<br/>Antineoplastic Combined Chemotherapy Protocols--adverse effects<br/>Bendamustine Hydrochloride--administration & dosage<br/>Female<br/>Humans<br/>Lenalidomide<br/>Lymphoma, B-Cell--drug therapy<br/>Male<br/>Middle Aged<br/>Remission Induction--methods<br/>Rituximab--administration & dosage<br/>Salvage Therapy<br/>Survival Rate<br/>Thalidomide--administration & dosage